Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine

Journal of Psychopharmacology

Volumn 22, Issue 3, 2008, Pages 323-329

  Ohlsen, R I ^a   Williamson, R ^a   Yusufi, B ^b   Mullan, J ^c   Irving, D ^c   Mukherjee, S ^b   Page, E ^d   Aitchison, K J ^a   Barnes, T R E ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse drug reaction reporting systems; Antipsychotic agent; Interrater reliability

Indexed keywords

CLOZAPINE; PROLACTIN;

ADULT; AGED; ANTIPSYCHOTIC NON NEUROLOGICAL SIDE EFFECTS RATING SCALE; ARTICLE; BLOOD DYSCRASIA; BLURRED VISION; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIABETES MELLITUS; DIARRHEA; DYSLIPIDEMIA; DYSPHORIA; DYSPNEA; ECG ABNORMALITY; ECTOPIC HORMONE PRODUCTION; EJACULATION DISORDER; EMOTIONAL DISORDER; EMOTIONAL NUMBING; ENERGY; ERECTILE DYSFUNCTION; FACE EDEMA; FACIES; FEMALE; FEVER; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERSALIVATION; HYPERTENSION; INTERRATER RELIABILITY; KAPPA STATISTICS; LASSITUDE; LETHARGY; LIBIDO DISORDER; LIVER DYSFUNCTION; MALE; MEMORY DISORDER; MENSTRUATION DISORDER; MENTAL CONCENTRATION; MENTAL PATIENT; MICTURITION DISORDER; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NIGHT SLEEP; NOCTURNAL ENURESIS; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; QT PROLONGATION; RASH; RATING SCALE; RESPIRATORY TRACT DISEASE; SEDATION; SEIZURE; SEXUAL AROUSAL DISORDER; SIDE EFFECT; SLEEP PATTERN; SWEATING; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; OBSERVER VARIATION; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS;

EID: 45349084495     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108091069     Document Type: Article

References (43)

1. Agresti, A. (1990) Categorical Data Analysis. New York: Wiley Series in probability and Statistics.
2. Altman, DG (1991) Practical Statistics for Medical Research. London, England: Chapman & Hall/CRC.
3. Barnes, TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Barnett, AH, Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, R., et al. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 21: 357-373.
5. Basu, A., Pereira, J., Aitchison, KJ (2007) The pharmacological management of schizophrenia. In: Stein, G, Wilkinson, G, (eds). College Seminar Series in General Adult Psychiatry, second ed. London: Gaskell (Royal College of Psychiatrists).
6. Bennett, J., Done, J., Harrison-Read, P., Hunt, B. (1995) Development of a rating scale/checklist to assess the side-effects of antipsychotics by community psychiatric nurses. In: White, E, Brooker, C, (eds). Community Psychiatric Nursing: A Research Perspective, vol. 3. London: Chapman and Hall.
7. Cohen, J. (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70: 213-220.
8. Davis, JM, Chen, N., Glick, ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
9. Day, JC, Wood, G., Dewey, M., Bentall, RP (1995) A self-rating scale for measuring side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166: 650-653.
10. Electronic Medicines Compendium (eMC) Amisulpride (Solian), Summary of Product Characteristics (Sanofi-Aventis) (last updated 2005). http://www.medicines.org.uk (accessed July 2007).
11. Electronic Medicines Compendium (eMC) Aripiprazole (Abilify), Summary of Product Characteristics (Bristol-Myers Squibb Pharmaceuticals Limited) (last updated 2007). http://www.medicines. org.uk (accessed July 2007).
12. Electronic Medicines Compendium (eMC) Clozapine (Clozaril), Summary of Product Characteristics (Novartis Pharmaceuticals UK Ltd) (last updated 2005). http://www.medicines.org.uk (accessed July 2007).
13. Electronic Medicines Compendium (eMC) Olanzapine (Zyprexa), Summary of Product Characteristics (Eli Lilly and Company Limited) (last updated 2006). http://www.medicines.org.uk (accessed July 2007).
14. Electronic Medicines Compendium (eMC) Quetiapine (Seroquel), Summary of Product Characteristics (AstraZeneca UK Limited) (last updated 2007). http://www.medicines.org.uk (accessed July 2007).
15. Electronic Medicines Compendium (eMC) Risperidone (Risperdal Consta), Summary of Product Characteristics (Janssen-Cilag Ltd) (last updated 2007). http://www.medicines.org.uk (accessed July 2007).
16. Electronic Medicines Compendium (eMC) Risperidone (Risperdal tablets), Summary of Product Characteristics (Janssen-Cilag Ltd) (last updated 2007). http://www.medicines.org.uk (accessed July 2007).
17. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, revised ed. Washington, DC: US Department of Health, Education, and Welfare.
18. Haddad, PM, Wieck, A. (2004) Antipsychotic induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291-2314.
19. Jones, PB, Barnes, TRE, Davies, L., Dunn, G., Lloyd, H., Hayhurst, KP, et al. (2006) Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 63: 1079-1087.
20. Karow, A., Czekalla, J., Dittman, RW, Schacht, A., Wagner, T., Lambert, M., et al. (2007) Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 68: 75-80.
21. Landis, JR, Koch, GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-174.
22. Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
23. Lingjaerde, O., Ahifors, U., Bech, P., Dencker, S., Elgen, K. (1987) The UKU side-effect rating scale. Acta Psychiatr Scand 34 (Suppl. 76). 1-100.
24. Marder, SR, Essock, SM, Miller, AL, Buhanan, RW, Csey, DE, Davis, JM, et al. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
25. Mir, A., Shivakumar, K., McAllister, V., Holloway, F., O'Keane, V., McCrone, P., et al. (2006 a) Change in sexual dysfunction on switching to aripiprazole. Schizophrenia Res, 81 (Suppl.). 137-138.
26. Mir, A., Shivakumar, K., McAllister, V., Holloway, F., O'Keane, V., McCrone, P., et al. (2006 b) Change in sexual dysfunction on switching to aripiprazole. J Psychopharmacol, 20 (Suppl.). A41.
27. Mir, A., Shivakumar, K., Williamson, RJ, McAllister, VDM, O'Keane, V., Aitchison, KJ (in press) Change in sexual dysfunction on aripiprazole: a switching or add-on study. J Psychopharmacol. first published on February 28, 2008 as doi:10.1177/0269881107082901.
28. Molokhia, M., McKeigue, P. (2006) EUDRAGENE: European Collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7: 633-638.
29. Naber, D., Karow, A. (2001) Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 11 (Suppl. 4). S391 - S396.
30. Naber, D., Moritz, S., Lambert, M., Pajonk, F., Holzbach, R., Mass, R., et al. (2001) Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50: 79-88.
31. National Institute for Clinical Excellence (2002) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE.
32. Pirmohamed, M., Darbyshire, J. (2004) Collecting and sharing information about harms. BMJ 329: 6-7.
33. Riedel, M., Müller, N., Strassnig, M., Spellman, I., Engel, RR, Musil, R., et al. (2005) Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia in the treatment of predominantly negative symptoms Eur Arch Psychiatry Clin Neurosci 255: 432-437.
34. Shivakumar, K., Mir, A., McAllister, V., O'Keane, V., McCrone, P., Holloway, F., et al. (2006) Aripiprazole switching strategies in community patients with psychosis. Schizophr Res 86 (Suppl.). S134.
35. Shrout, PE (1998) Measurement reliability and agreement in psychiatry. Stat Methods Med Res 17: 301-317.
36. Sprague, DA, Loewen, PS, Raymond, CB (2004) Selection of atypical antipsychotics for the treatment of schizophrenia. Ann Pharmacother 38: 313-319.
37. Simpson, GM, Angus, JWS (1970) A rating scale for extra pyramidal side-effects. Acta Psychiatr Scand 212 (Suppl.). 11-19.
38. Smith, SM, O'Keane, V., Murray, R. (2002) Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 181: 49-55.
39. Tandon, R., Jibson, MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28 (Suppl. 1). 9-26.
40. Thomas, P. (2007) The stable patient with schizophrenia. From antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol 17 (Suppl. 2). S115 - S122.
41. Viera, AJ, Garrett, JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360-363.
42. Yusufi, B., Mukherjee, S., Aitchison, K., Dunn, G., Page, E., Barnes, TRE (2005) Reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS). J Psychopharmacol 19 (Suppl). A10.
43. Yusufi, BZ, Mukherjee, S., Flanagan, RJ, Paton, C., Dunn, G., Page, E., et al. (2007) Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 22: 238-243.